Biomaterials at the interface of bone-derived factors and inter-organ communication: Current evidence and future perspectives. [PDF]
Bioact MaterJi L, Zhu F, Wang X, Wang J, Liu C.
europepmc +1 more source
Cardiovascular Outcomes Following Therapeutic Sclerostin Inhibition Compared With Alternative Anabolic Therapies: A Real-World Propensity Score-Matched Analysis. [PDF]
J OsteoporosBarnett MJL, Lam J, Anastasopoulou C.
europepmc +1 more source
Sequential Anabolic and Antiresorptive Treatment Promotes Medication-Related Osteonecrosis of the Jaw in Mice. [PDF]
Oral DisAn SY, Park HS, Kim RH, Kim MY.
europepmc +1 more source
Increased Serum Levels of Dickkopf-1 and Sclerostin as WNT Signaling Pathway Inhibitors in Celiac Disease Patients. [PDF]
Immun Inflamm DisAl-Ani MNT +5 more
europepmc +1 more source
New findings in diabetic kidney disease: correlation and enhanced combined diagnostic value of sclerostin and 25(OH)VD. [PDF]
Front Endocrinol (Lausanne)Niu C +7 more
europepmc +1 more source
Editorial: Emerging therapies for metabolic bone diseases. [PDF]
Front Endocrinol (Lausanne)Falchetti A, Gennari L.
europepmc +1 more source
Metformin attenuates diabetic osteoporosis via the miR-21 mediated Mef2c/Sost pathway. [PDF]
Front Endocrinol (Lausanne)Liu L +8 more
europepmc +1 more source
Romosozumab and Cardiovascular Safety: Bridging the Gap between Clinical Trials and Real-World Evidence. [PDF]
Endocrinol Metab (Seoul)Kim BJ.
europepmc +1 more source
Romosozumab in postmenopausal women with classical Osteogenesis imperfecta. [PDF]
Arch OsteoporosBartosik M +4 more
europepmc +1 more source
Periodontitis as a Model for Inflammatory Uncoupling of Bone Remodeling. [PDF]
J Periodontal Resde Molon RS +4 more
europepmc +1 more source